Patients facing higher rates of tumor-associated mortality also tend to exhibit higher levels of specific cytokines (e.g., IL-6, IL-17A, IL-22, and transforming growth factor-β (TGF-β)) (26). This evidence concerns the gene TGFB1 and neoplasm.